近11亿美元，“药王”再获海外大单！创新药BD交易高峰期将临，100%创新药研发标的“520880”资金面火热

Group 1 - Core viewpoint: Heng Rui Medicine has achieved significant milestones in overseas licensing agreements for its innovative drugs, indicating strong growth potential in the pharmaceutical sector [1][2]. - The company licensed its innovative drug SHR-A1811 to Glenmark Specialty for a $18 million upfront payment, with potential milestone payments up to $1.093 billion [1]. - Earlier in September, Heng Rui Medicine entered an exclusive licensing agreement with Braveheart Bio for its Myosin small molecule inhibitor HRS-1893, receiving a $65 million upfront payment and potential milestone payments up to $1.013 billion [1]. Group 2 - The A-share market for innovative drugs showed a strong rebound on September 24, with Heng Rui Medicine's A-shares rising by 3.37% [2]. - In contrast, the Hong Kong market for innovative drugs remained sluggish, with Heng Rui Medicine's Hong Kong shares increasing by 1.6% while the overall Hong Kong innovative drug ETF fell by 0.64% [4]. - The Hong Kong innovative drug ETF has seen significant inflows, accumulating nearly 680 million yuan over 14 consecutive days, indicating strong investor interest [6]. Group 3 - The Hong Kong innovative drug ETF (520880) focuses exclusively on innovative drug development, excluding CXO companies, and has shown a year-to-date increase of 119.75%, outperforming other indices [8][9]. - The ETF's strategy aims to enhance its performance by avoiding the influence of CXO companies, which may lead to stronger gains when the innovative drug market rallies [9].